Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | TYK2 | P29597 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17397127 | 0.88 | RAB9A (0.57) | NPC1RAB9AATMALDH1A1JAK2 | |
| SCHEMBL23015751 | 0.86 | NPC1 (0.64) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL21349105 | 0.86 | HTR1F (0.54) | NPC1RAB9AALDH1A1JAK2DEGS1 | |
| SCHEMBL16594482 | 0.86 | CCNA2 (0.56) | NPC1RAB9AALDH1A1BRAFKMT2A | |
| SCHEMBL20016542 | 0.85 | MEN1 (0.58) | NPC1RAB9AALDH1A1BRAFKMT2A | |
| SCHEMBL2176413 | 0.80 | NPC1 (0.89) | NPC1RAB9AATMALDH1A1KMT2A | |
| SCHEMBL17065565 | 0.80 | NPC1 (0.89) | NPC1RAB9AATMALDH1A1KMT2A | |
| SCHEMBL24726481 | 0.80 | SIRT2 (0.61) | NPC1RAB9AALDH1A1BRAFKMT2A | |
| SCHEMBL7669653 | 0.80 | RAB9A (0.64) | NPC1RAB9AATMALDH1A1JAK2 | |
| SCHEMBL84076 | 0.80 | L3MBTL1 (0.52) | JAK2TYK2BRAFMAPKAPK2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015057992-A1 | BTK INHIBITORS FOR HEMATOPOIETIC MOBILIZATION | IZUMI RAQUEL (US) | 2015-04-23 | — | — | WO | claimed |
| US-20240024314-A1 | Methods of Treating Splenomegaly | TELIOS PHARMA, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-11642343-B2 | Methods of treating splenomegaly | TELIOS PHARMA, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220387434-A1 | COMBINATION OF A BTK INHIBITOR AND AN MDM2 INHIBITOR FOR CANCER TREATMENT | QUOGUE IP HOLDINGS LLC (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220184069-A1 | METHODS OF TREATING SPLENOMEGALY | TELIOS PHARMA, INC. (US) | 2022-06-16 | — | — | US | disclosed |
| WO-2015057992-A1 | BTK INHIBITORS FOR HEMATOPOIETIC MOBILIZATION | IZUMI RAQUEL (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387434-A1 | COMBINATION OF A BTK INHIBITOR AND AN MDM2 INHIBITOR FOR CANCER TREATMENT | BTK, BCL9L, BCL9 | NPC1 3690/4885RAB9A 2681/4885ATM 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.